← Issue №14/ week of Oct 4, 2026/Hepatology

Association of Aspirin With Improved Clinical Outcomes and Survival in Patients With Compensated Cirrhosis: A Propensity Score-Matched Study of 25 782 Individuals.

From GI Signals issue №14: what this paper found, what it changes, and where it sits against the current standard of care, reviewed by Simon Mathews, MD.

Hepatology retrospective · n=25,782 · Oct 1, 2026 · J Gastro Hep · IF 3.5

Association of Aspirin With Improved Clinical Outcomes and Survival in Patients With Compensated Cirrhosis: A Propensity Score-Matched Study of 25 782 Individuals.

New evidencecirrhosisportal hypertensionvariceal bleedinghepatocellular carcinoma
Clinical takeawayConsider aspirin for adults with compensated cirrhosis without prior HCC, particularly those with high cardiovascular risk, after weighing bleeding risk.
What it foundAspirin reduced cirrhosis decompensation risk (HR 0.75 at 12 months, 17.8% vs 22.7%) and mortality (NNT 20 at 12 months) compared to no aspirin in adults with compensated cirrhosis without prior HCC, despite an increased risk of nonvariceal bleeding (NNH 143 at 12 months).
ContextChallenges current practice by suggesting aspirin may prevent decompensation in cirrhosis, a condition with limited pharmacologic options.
No standard claimed for this paper

Every paper is compared to the standard governing its question. This one is not: either no standard in the corpus matches it, or the comparison did not hold up on review and was withdrawn rather than published unverified. Both are logged.

Abbarh S … Siepmann T · Journal of Gastroenterology and Hepatology · IF 3.5 · PubMed ↗Permalink
← Read the whole of issue №14 Every paper GI Signals surfaces gets a page like this one. All issues